GlassScriptPhysician profile
John Thomas Rooney
NPI 1972573533
$2,659.68
in general payments reported to CMS, 2019-2025
27 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $80.25 · 2021: $284 · 2022: $233 · 2023: $557 · 2024: $449 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $369.47 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $301.49 | 2019-2025 | Linzess, Viberzi |
| Glaxosmithkline, LLC. | $273.34 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.24 | 2019-2024 | |
| Pfizer INC. | $222.02 | 2021-2025 | |
| Novo Nordisk INC | $210.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $198.80 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $162.62 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $107.14 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $86.36 | 2022-2023 | |
| Astellas Pharma US INC | $74.98 | 2023-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $50.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $50.47 | 2019-2024 | Spravato |
| Almatica Pharma LLC | $50.18 | 2023 | Loreev Xr, Sertraline Hcl |
| Biohaven Pharmaceuticals, INC. | $46.79 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $29.89 | 2019 | |
| Amgen INC. | $29.37 | 2019 | |
| Tempus Ai, INC | $23.37 | 2024 | Tempus Pixel |
| Novartis Pharmaceuticals Corporation | $22.44 | 2022 | |
| Edwards Lifesciences Corporation | $21.12 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Recordati_rare_diseases_inc. | $20.93 | 2025 | Isturisa |
| Mdd US Operations, LLC | $14.46 | 2019 | |
| Merck Sharp & Dohme LLC | $14.03 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.31 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.23 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.48 | 2019 | |
| Allergan, INC. | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.